Enhanced response to basiliximab in a patient with aplastic anemia after treatment with standard immunosuppression.
Berman
Jessica A
JA
Patel
Kashyap
K
Caro
Jaime
J
D000208:Acute Disease; D000328:Adult; D000741:Anemia, Aplastic / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000077552:Basiliximab; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006505:Hepatitis / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D012074:Remission Induction; D013601:T-Lymphocytes
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D009173:Mycophenolic Acid